The COVID-19 pandemic is having a significant effect on physician practices in Orthopedics and Sports Medicine, including the number of elective procedures being postponed, when normal operations might resume, the adoption of telemedicine, delivery of physician education and interactions with industry. To find out more, SmartTRAK Analyst Freddy Buntoum interviewed Steven Sampson, DO, founder of The Orthobiologic Institute (TOBI) and an internationally-recognized expert in the field of non-surgical orthopedics and the science of sports medicine. To hear Dr. Sampson’s take on how things might evolve throughout the rest of 2020, and how his practice and organization are supporting patients and other stakeholders, click on the following video to listen to the interview recorded via Uberconference (25:20 minutes). A transcript of the interview can be downloaded below.
3 min read
3 min read
For the fourth quarter of 2019, WW Soft Tissue Fixation Market revenue was up +3.7% YoY. Aggregate growth for the quarter especially benefited from healthy and continued revenue gains in the Hip Labral repair segment, which was up +8.9% YoY. And, to a smaller extent, the Meniscal repair and the Shoulder repair segments also contributing to the overall WW market growth in Q419 with YoY increases of 4.4% and 4.1%, respectively, based on SmartTRAK Financial Dashboard. Similar to other orthopedic markets, such as the Joint replacement market, Soft Tissue Fixation is typically seasonal with lower sales during Q3 and recovery in Q4 driven by a year-end increase in the number of elective procedures and stronger product push as competitors race to finish the year at or above their respective budget projections.
9 min read
The Biologic Association kicked off its very 1st Summit (Feb 5-7, 2020 in Carlsbad, CA) with what turned out to be a big crowd-pleaser. Initially set up as a “by invitation only” attendance, the Summit’s opening program, “Biologic Association Think Tank” raised such a high level of interest that everyone in attendance was ultimately let into the session.
The format for the Think Tank was quite similar to the hugely popular television show “Shark Tank.” Only in this session, the “school of fish” (contestants/presenters) included a lineup of industry and/or academic researchers in the field of Orthobiologics who gave presentations on their respective lead product candidates.
1 min read
Overall, 2019 was a good recovery year for the US Joint Fluid market with Single-injection treatment options at the helm
For Q419, revenue in the US Joint Fluid market was up, recovering fairly well from a year ago according to SmartTRAK Financial Dashboard. Aggregate growth for the quarter was attributable to a double-digit revenue growth in single injection. Stronger demand and heavy product push in that segment, especially at year-end, was offset to a certain extent by revenue declines in 3- and 5-injections.
Among the many topics covered in the comprehensive Q419 US Joint Fluid Market Recap* are:
12 min read
The GID Group – Prepping to revolutionize Regenerative Medicine with an innovative modular tissue processing platform
In December, at IFATS 2019, William “Bill” Cimino, PhD, CEO of The GID Group (GID) sat down with SmartTRAK to discuss the Company’s novel modular tissue processing platform, which reduces an entire GMP cell-processing facility to a single disposable device, enabling physicians to extract and process adipose tissue in real time for use in a wide range of applications.
GID is a privately held, clinical stage cellular medicine company currently working on developing a tissue processing platform, the GID SVF-2 device, that enables cell-based treatments.
To find out more about the GID Group, its revolutionary technology and product candidate, click on the following video to listen to SmarTRAK’s interview with Bill Cimino, recorded live at the IFATS Annual Meeting held in Marseille, France December 3-7, 2019. A transcript of the interview is also provided below.
4 min read
For the third quarter of 2019, the WW Soft Tissue Fixation Market revenue was up +3.4% YoY. Aggregate growth for the quarter benefited from solid revenue growth in the Hip Labral Repair segment, which was up +10.1% YoY, based on SmartTRAK Financial Dashboard.
Focusing on the US region, the Soft Tissue Fixation market was up YoY. However, on a sequential basis, growth was slightly down, attributable to the seasonal nature of Sports Medicine where many surgeries are elective with Q4 generally seeing high procedure volumes. Aggregate growth for Q319 was pulled by notable growths in the Shoulder Soft Tissue Fixation and the Hip Labral Repair segments. Although Knee Soft Tissue Fixation represents the 2nd largest segment, revenue growth was marginal, with the moderate growth seen steady at slightly above ...
2 min read
For the third quarter of 2019, the US Joint Fluid market revenue was essentially flat, +0.2% vs Q318. Aggregate growth for the quarter was pulled into slightly positive territory by a solid revenue growth of 14.3% YoY in single injection, according to the recently published SmartTRAK Financial Dashboard. However, strength in that segment was barely enough to counter revenue declines in 3- and 5-injections, while the 2-injection segment is still not large enough to make a significant contribution to the overall recovery of the US Joint Fluid market.
The single-injection segment held on to the market lead for Q319. Despite pricing pressure between competitors in this segment, revenue growth further solidifies the trend that the HA market is moving to the lowest treatment cycle. For Q319, 3-injection products dropped down, strained by heavy competition and a persistent price war. Trailing behind is the 5-injections with...
Among the many topics covered in the comprehensive Q319 US Joint Fluid Market Recap* are:
7 min read
in Orthobiologics from the 10th PRP & Regenerative Medicine Symposium, hosted by TOBI,
4 min read
4 min read
OrthogenRx CEO & Founder Michael Daley talks about the Company’s new 3-injection HA product, TriVisc and what will come next.
Michael Daley, CEO & Founder of OrthogenRx, a US medical device company focused on treatments for musculoskeletal conditions, talked about TriVisc, the Company’s new 3-injection hyaluronic acid (HA) product for knee osteoarthritis, as well as the future at OrthogenRx, in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting held March 12-14, 2019 in Las Vegas, NV.
What is the rational for OrthogenRx to bring TriVisc now to a very crowded 3-injection HA segment?
To have a presence in the entire US HA market, OrthogenRx aims to provide...